



DIO9 Rec'd PCT/PTO _1 O MAR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hirth-Dietrich, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/009666

Title: Dibenzoxazepines

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

11

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Tilman Breitenstein

Limited Recognition under 37 CFR § 11.9(b)

Agent for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2226

Facsimile: (203) 812-6459

					-						19 F 9 PL	1/P10	<u>1 U MA</u>	<u>R 2005</u>	
Form PTC (Modified	U.S. Depart of Commerce Patent and anademark Office							Serial No.	Art Uni	t iling	Date	Atty. Docl	ket No.		
(modified) Fatch and statemark Office									[To Be Assigne			Le A 36			
THE PLANTS OF THE PARTY OF THE									Applicant(s)		1	115	27z	00	
INFORMATION DISCLOSURE CITATION									Applicant(s) 10/527388						
										 			-		
							U.	S. PA	TENT DOCU	MENTS					
DOCUMENT NO.									DATE	NAME	CLASS	SUB-	FILING DATE		
									(MM/DD/YY)			CLASS	IF APPROPRIATE		
									1						
		 		-	-		+	-					<u> </u>		
	<u> </u>		-	-	 	†		<u> </u>	 				-		
		ļ	ļ		ļ	ļ	ļ	<u> </u>							
									İ						
			1							-			-		
	ļ	ļ	-	-	ļ	-	-								
]	FORI	EIGN	PATENT DO	CUMENTS					
DOCUMENT NO.									DATE	DATE COUNTRY PRIMARY SUB-		TDANIC	TRANSLATION		
*		DOCUMENT NO.							(DD/MM/YY)	COUNTRY	CLASS	CLASS	YES NO		
	1721		Ι Δ	T =	T 4"	1 0	1 -	Т .	20/06/02	ED	<u> </u>	-	1123	110	
	F1	0	0	5	4	9	5	1	30/06/82	EP				<u> </u>	
	F2	0	0	4	8	6	0	3	24/08/00	wo		=			
	-	 			1		<u> </u>	<u> </u>					 	 	
	<u> </u>				ļ		ļ	ļ						ļ .	
				i											
			<u> </u>	 		-					 		 	 	
														<u></u>	
			ОТИ	rn n	ומימומו	n tenia	TEC (r 1	J: A41 71	241 - D.4 - D	4' 4 D	4- \			
	R1		orn ider.						ding Author, T leoside Inhibite				se 2 T	ricyclic	
									epinones," J. Me				. 2. 1	rie y erie	
	R2 [Database CA Online] Chemical Abstracts Service, Columbus, Ohio, US. Chugai Pharmaceutical C										Co., Ltd.	, Japan:			
		"Dib	enzox	azepir	none D	erivat	ives,"	Retrie	ved from STN, D	atabase Accessi	on No. 100:19	1915.			
		_													
		ĺ													
															
					<u></u>	. <u> </u>									
								_ =							
EXAMINE	ER								DATE	CONSIDERED					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.